北京招聘

职位描述：

Responsibility:

Overview

This role will be acting as an individual contributor under the lead of the China RA Manager.

1. The major responsibility is to manage Medical Devices Registration activities, including new registrations, licenses maintenance and follow up China Regulations (60%)

a. Deliver requirements clearly to headquarter regarding on all submissions

b. Good at communicating with China Authorities

c. Provide suggestions/assessments on regulation changing.

2. The third responsibility is to assist managing Drugs registration activities when requested by China RA Manager (20%)

3. The second responsibility is to be a supporting role for other functions such as Quality Complaints, devices importation and distribution (20%)

Education:

§ Bachelor’s degree, nice to have education background on pharmaceuticals

§ Good written and oral communication skills in English.

§ Multitasking management, Sharing, Passion, Cooperative

举报 分享

Mallinckrodt, the Pharmaceuticals business of Covidien, is a vertically integrated leader in providing products used in diagnostic procedures and in the treatment of pain and related conditions. We are the largest U.S. supplier, by prescription, of opioid pain medications and a leading manufacturer of active pharmaceutical ingredients. We are also the largest global supplier of the medical isotope technetium-99m and an industry leader in radiopharmaceuticals, contrast media, and delivery systems. Mallinckrodt encompasses more than 5,500 dedicated employees around the globe, all focused on our core values of quality, integrity and service to meet the needs of patients globally. Please visit www.mallinckrodt.com to learn more about our business.

Established as G. Mallinckrodt & Company in 1867, the $2 billion St. Louis-based business was acquired by Tyco International in 2000. In 2007, Tyco spun off its healthcare business into Covidien, a leading global healthcare products company. On December 15, 2011, Covidien announced plans to spin off Mallinckrodt as a standalone public company. On February 1, 2013, Mallinckrodt submitted the initial filing of a Form 10 Registration Statement with the U.S. Securities and Exchange Commission. Covidien expects to complete the spin-off by mid-2013.

Mallinckrodt's mission is to reveal and relieve disease for a healthier world, and our vision expands on our mission - a world made healthier by building on our heritage of distinctive capabilities to provide patients with pharmaceuticals that reveal and relieve disease.